# FDA Inspection 1269921 - Revance Therapeutics, Inc. - May 01, 2025

Source: https://www.globalkeysolutions.net/records/fda_inspections/revance-therapeutics-inc/be88cb67-1a16-4e2f-8531-a6c276fb6212/
Source feed: FDA_Inspections

> FDA Inspection 1269921 for Revance Therapeutics, Inc. on May 01, 2025. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1269921
- Company Name: Revance Therapeutics, Inc.
- Inspection Date: 2025-05-01
- Classification: No Action Indicated (NAI)
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Office Name: Center for Drug Evaluation and Research

## Related Documents

- [FDA Inspection 1269921 - 2025-05-01](https://www.globalkeysolutions.net/api/records/fda_inspections/revance-therapeutics-inc/3536ce12-6e01-4d9f-ab95-f161973669b3/)

Company: https://www.globalkeysolutions.net/companies/revance-therapeutics-inc/33277fcf-5886-406e-8332-bc85057ba4bc

Office: https://www.globalkeysolutions.net/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c